Market News Archives

Clinical Success Pushes GeoVax Into Spotlight as A Multi-Antigen Vaccine Leader – ( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. September 15, 2025 590Views 0Likes

GeoVax Labs (Nasdaq: GOVX), an Atlanta-based biotechnology firm, has garnered attention following the release of promising Phase 2 clinical data for its multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, in patients with chronic lymphocytic leukemia (CLL). The findings, presented at the recent International Workshop…

If You Invested $1,000 in Tesla’s IPO, Here’s What It’s Worth After Elon Musk’s $1B Stock Purchase – ( $TSLA $SPY $QQQ )

by John F. Heerdink, Jr. September 15, 2025 705Views 0Likes

Investing $1,000 in Tesla (TSLA) stock at its June 2010 IPO would be worth over $23,290 today, reflecting the company’s staggering share appreciation since its debut at $17 per share and a current price of $395.94 per share. This remarkable journey encapsulates the…

Biotech Breakthrough: Serina Therapeutics Secures Insider Led Financing for SER-252 Registrational Trial in Neurology Pipeline – ( $SER $BHVN $XBI )

by John F. Heerdink, Jr. September 10, 2025 627Views 0Likes

Serina Therapeutics (NYSE American: SER), a biotechnology firm headquartered at the HudsonAlpha Institute in Huntsville, Alabama, has rapidly advanced its position in the neurology pipeline by leveraging its proprietary POZ Platform™. Over the past several months, the company has unveiled a series…

Oracle Stock Skyrockets Over 40% as AI-Powered Cloud Contracts Hit Record Highs ( $ORCL $SPY $NVDA )

by John F. Heerdink, Jr. September 10, 2025 550Views 0Likes

Oracle’s stock (ORCL) experienced a historic rally today, surging as much as 42% following news of unprecedented demand for its AI-driven cloud infrastructure and record-breaking contract wins. This marks Oracle’s largest single-day gain since the 1990s and sets a record for companies with market…

The InterGroup Corporation’s Hilton SF Stake Puts It at the Heart of San Francisco’s AI-Driven Revival – ( $AAPL $INTG $NVDA )

by John F. Heerdink, Jr. September 9, 2025 494Views 0Likes

The InterGroup Corporation (NASDAQ: INTG) is emerging as a compelling turnaround story in 2025, combining solid real estate assets with a strategic push to unlock shareholder value and capitalize on market dislocations. Recent Highlights and Stock Momentum In August, InterGroup’s (INTG) shares…

Anglo American and Teck Forge $53 Billion Copper Giant as Hecla Mining Surges ( $HL TECK-B.TO AAL.L $SLV )

by John F. Heerdink, Jr. September 9, 2025 413Views 0Likes

London-listed Anglo American (AAL.L) and Canada's Teck Resources (TECK-B.TO) have sealed a transformative, “merger of equals” deal that will reshape the mining landscape—creating a copper powerhouse with a combined market capitalization north of $53 billion, headquarters in Vancouver, and core operations spanning…

How $1,000 in NVIDIA’s 1999 IPO Became $6.7 Million: The Vision of Jensen Huang – ( $NVDA $SPY $QQQ )

by John F. Heerdink, Jr. September 6, 2025 785Views 0Likes

NVIDIA’s (NVDA) meteoric rise from Silicon Valley upstart to AI infrastructure leader is deeply intertwined with the vision and resilience of its founder-CEO, Jensen Huang. An immigrant who experienced hardship and displacement as a youth in Taiwan and the U.S., Huang sharpened…

Global Central Banks Drive Gold to New Record, Surpassing U.S. Bonds in Portfolios – ( $GLD $SPY )

by John F. Heerdink, Jr. September 2, 2025 406Views 0Likes

Gold has achieved a historic milestone in 2025, with central banks now holding more gold in their reserves than U.S. Treasuries for the first time since 1996—a shift signaling profound changes in global finance and monetary management. Central Banks Shift to Gold…

Beyond Daily Pills: Eupraxia’s Annual Therapy Could Revolutionize Eosinophilic Esophagitis Management – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 2, 2025 618Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is defining a new frontier in the treatment of eosinophilic esophagitis (EoE) with its innovative candidate, EP-104GI. This investigational therapy, developed with Eupraxia’s proprietary DiffuSphere™ technology, delivers long-lasting and locally targeted steroid treatment directly into the esophageal wall—offering…

Eupraxia Pharmaceuticals (NASDAQ: EPRX) Accelerates Toward Key Clinical Milestones—Wall Street Remains Bullish

by John F. Heerdink, Jr. August 28, 2025 711Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has recently achieved several pivotal milestones, signaling increased momentum in its late-stage clinical programs and drawing strong endorsements from Wall Street analysts, while shares of Eupraxia have risen ~100% over the last 12 months. The company’s clinical progress,…

Market News

Your Guide To Staying Informed In The Markets